personalized therapy

Optimizing Antithyroid Drug Duration in Graves’ Disease with Low TRAb: Evidence for Shorter Therapy

A propensity-weighted analysis suggests that shorter antithyroid drug therapy (<12 months) in Graves' disease patients with low baseline TRAb is broadly comparable to the standard 12-18 months in preventing relapse, supporting indiv